IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Changes in ALPP in Women With SUI Following Air Instillation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
More than 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during everyday activities that put temporary stress on the abdomen and bladder, such as laughing, coughing, and walking. For women with SUI, this pressure often causes urine to leak involuntarily. SUI affects women of all ages including young mothers, pre-menopausal women, and seniors, and can result in significant emotional distress. Current solutions for SUI include disposable pads, behavioral treatment (pelvic floor physical therapy) and surgical intervention. Patients with SUI who failed conservative treatment and wish to be further treated by a surgery may require further work-up by urodynamic study in which abdominal leak point pressures (ALPP) defined and reflect the severity of SUI.
There is continuous need to develop less invasive treatments for SUI that could minimize the use of pads, could be an alternative to painful, costly surgical procedure. The Trendlines Group lab solution is a non-surgical alternative in the treatment of SUI. The concept of the future treatment solution is based on simple physics: injecting a small amount of air into the urinary bladder, which eliminates or greatly reduces involuntary urinary leakage. The air bubble acts as a "shock absorber" to reduce the temporary pressure increase in the bladder that causes urinary leakage. The concept for the new treatment has been tested in a lab environment using lab jig tests and pig urinary system (bladder and urethra). The lab tests showed significant improvement in the bladder pressure when the treatment was implemented by suspending the stress pressure to a level that will not cause urine leakage.
| Condition | Intervention | Phase |
|---|---|---|
| Stress Urinary Incontinence | Other: SUI 1 | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Changes in Abdominal Leak Point Pressures in Women Stress Urinary Incontinence Following Intravesical Air Instillation During Urodynamic Study |
- change in abdominal leak point pressure [ Time Frame: 1 day ]to verify the concept of a possible future treatment in the clinical setup by checking physical effect of dumping pressure (decrease in ALLP) by inserting 50 ml of air into the bladder during the urodynamic study in patients with SUI.
- adverse events as a measure of safety and tolerability [ Time Frame: 1 week ]
| Estimated Enrollment: | 10 |
| Study Start Date: | March 2015 |
| Estimated Study Completion Date: | December 2016 |
| Estimated Primary Completion Date: | December 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: SUI 1
Patients will perform urodynamic study before and after instillation of 50 ml of air
|
Other: SUI 1
instillation of 50ml of air into the urinary bladder before the urodynamic test
Other Name: 50ml of air instillation into the bladder
|
Detailed Description:
More than 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during everyday activities that put temporary stress on the abdomen and bladder, such as laughing, coughing, and walking. For women with SUI, this pressure often causes urine to leak involuntarily. SUI affects women of all ages including young mothers, pre-menopausal women, and seniors, and can result in significant emotional distress. Current solutions for SUI include disposable pads, behavioral treatment (pelvic floor physical therapy) and surgical intervention. Patients with SUI who failed conservative treatment and wish to be further treated by a surgery may require further work-up by urodynamic study in which abdominal leak point pressures (ALPP) defined and reflect the severity of SUI.
There is continuous need to develop less invasive treatments for SUI that could minimize the use of pads, could be an alternative to painful, costly surgical procedure. The Trendlines Group lab solution is a non-surgical alternative in the treatment of SUI. The concept of the future treatment solution is based on simple physics: injecting a small amount of air into the urinary bladder, which eliminates or greatly reduces involuntary urinary leakage. The air bubble acts as a "shock absorber" to reduce the temporary pressure increase in the bladder that causes urinary leakage. The concept for the new treatment has been tested in a lab environment using lab jig tests and pig urinary system (bladder and urethra). The lab tests showed significant improvement in the bladder pressure when the treatment was implemented by suspending the stress pressure to a level that will not cause urine leakage.
Following positive results of this proof of concept study we could plan further innovative device to treat SUI in women.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women
- Age >18 years old
- SUI: pure or stress predominant mixed urinary incontinence.
- Failure of conservative treatment who desires surgical procedure for SUI.
- Signed informed consent for the trial and urodynamic study.
- Negative urine culture.
Exclusion Criteria:
- Neurogenic SUI
- Unable or unwilling to sign informed consent for the trial and urodynamic study.
- Patient who does not will a surgery for SUI
- Prior pelvic or lower abdominal malignancies
- Prior pelvic radiation or surgery except anterior/posterior colporrhaphy or hysterectomy (with or without oophorectomy) for benign disease.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02113670
| Contact: Michael Vainrib, M.D. | 972584705941 | mvainrib@gmail.com |
| Israel | |
| Meir Medical Center | Recruiting |
| Kfar Saba, Israel, 44410 | |
| Contact: Michael Vainrib, M.D. 972584705941 mvainrib@gmail.com | |
| Principal Investigator: Michael Vainrib, M.D. | |
More Information
| Responsible Party: | Meir Medical Center |
| ClinicalTrials.gov Identifier: | NCT02113670 History of Changes |
| Other Study ID Numbers: |
TrendLinesSUI |
| Study First Received: | March 28, 2014 |
| Last Updated: | September 26, 2016 |
Keywords provided by Meir Medical Center:
|
stress urinary incontinence abdominal leak point pressure urodynamic study |
Additional relevant MeSH terms:
|
Urinary Incontinence, Stress Urinary Incontinence Enuresis Urination Disorders Urologic Diseases Lower Urinary Tract Symptoms |
Urological Manifestations Signs and Symptoms Behavioral Symptoms Elimination Disorders Mental Disorders |
ClinicalTrials.gov processed this record on September 21, 2017